Peyrin-Biroulet, L.
Bossuyt, P.
Bettenworth, D.
Loftus, E. V. Jr.
Anjie, S. I.
D’Haens, G.
Saruta, M.
Arkkila, P.
Park, H.
Choi, D.
Kim, D- H.
Reinisch, W. http://orcid.org/0000-0002-2088-091X
Funding for this research was provided by:
Celltrion Healthcare
Medical University of Vienna
Article History
Received: 19 September 2023
Accepted: 14 December 2023
First Online: 18 March 2024
Declarations
:
: Laurent Peyrin-Biroulet has received personal fees from AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Enterome, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Hikma, Index Pharmaceuticals, Inotrem, Janssen, Lilly, MSD, Mylan, Nestlé, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Theravance, Tillotts, and Vifor. Peter Bossuyt has received research grants from AbbVie, Amgen, Celltrion, Mylan, Pfizer, and Takeda; lecture fees from AbbVie, Celltrion, Janssen, Lilly, and Takeda; and consulting fees from AbbVie, Arena, BMS, Celltrion, Dr Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda, and Tetrameros. Dominik Bettenworth is on the advisory board or has acted as a consultant for AbbVie, Amgen, Arena, Atheneum, BNG Service GmbH, BMS, CED Service GmbH, Celltrion, DGVS, Diaplan, Else Kröner-Fresenius Foundation, Falk Foundation, Galapagos, GuidePoint, Impulze, Ferring, Janssen, Lilly, Medical Tribune, MedTriX, MSD, Mylan, Onkowissen, Pharmacosmos, Pfizer, Roche, Sandoz, Takeda, Tetrameros, Thieme, Tillotts, UCB Biopharma, Viatris, and Vifor Pharma. Edward Loftus has acted as a consultant for AbbVie, Alvotech, Amgen, Arena, Avalo Therapeutics, Boehringer Ingelheim, BMS, CALIBR, Celltrion, Eli Lilly, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Scopes, Janssen, KSL Diagnostics, Morphic, Ono Pharma, Pfizer, Protagonist, Scipher, Sun Pharma, Surrozen, Takeda, and UCB; received research support from AbbVie, AstraZeneca, BMS, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Takeda, Theravance, and UCB; and is a shareowner of Exact Sciences. Suzanne Anjie declares no conflicts of interest. Geert D’Haens has received consultancy fees from AbbVie, Agomab, AM Pharma, AMT, Arena, AstraZeneca, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Gilead, GlaxoSmithKline, Gossamer Bio, Immunic, Index Pharmaceuticals, Johnson & Johnson, Kaleido, Origo, Pfizer, Polpharma, ProciseDx, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist, and Roche; speaker fees from AbbVie, Arena, BMS, Galapagos, Gilead, Pfizer, and Takeda; and served on a Data Monitoring Board for AstraZeneca, Galapagos, and Seres. Masayuki Saruta has received honoraria from AbbVie, EA Pharma, Gilead, Janssen, Mitsubishi Tanabe, and Takeda; writing fees from EA Pharma; grants for commissioned/joint research from EPS Corporation; and scholarship grants from EA Pharma, Kissei Pharmaceutical, Mochida Pharmaceutical, and Zeria Pharmaceutical. Perttu Arkkila has been an advisory board member of Celltrion and Janssen, is a stockholder of Orion Pharma, and has attended educational events organized and funded by Takeda. HyunSoo Park is an employee of Celltrion Healthcare Co., Ltd. Dasom Choi is an employee of Celltrion Healthcare Co., Ltd. Dong-Hyeon Kim is an employee of Celltrion Healthcare Co., Ltd. Walter Reinisch has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Celltrion, Falk Pharma, Ferring, Janssen, MEDICE, Mitsubishi Tanabe, MSD, Pfizer, Pharmacosmos, PLS Education, Roche, Shire, Takeda, Therakos, and Vifor; served as a consultant for AbbVie, Algernon, Amgen, Arena, Astellas, AstraZeneca, Bioclinica, Boehringer Ingelheim, BMS, Calyx, Celgene, Celltrion, Eli Lilly, Ernst & Young, Falk Pharma, Ferring, Fresenius, Galapagos, Gatehouse Bio, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Landos Biopharma, LivaNova, Mallinckrodt, MedAhead, MedImmune, Mitsubishi Tanabe, MSD, Nash Pharmaceuticals, Nestlé, Novartis, OMass, Otsuka, Parexel, Periconsulting, Pfizer, Pharmacosmos, Prometheus, Protagonist, Provention Bio, Quell Therapeutics, Robarts Clinical Trials, Roche, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpoint Medical, Sigmoid, Sublimity, Takeda, Teva Pharma, Therakos, Theravance, Vifor, and Zealand; received support for attending meetings and/or travel from AbbVie, Janssen, and Takeda; and served on a Data Safety Monitoring Board or advisory board for OSE Pharma.